
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from... Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -2.65957446809 | 1.88 | 2.09 | 1.75 | 665201 | 1.92228207 | CS |
4 | -0.61 | -25 | 2.44 | 2.545 | 1.75 | 558067 | 2.12792768 | CS |
12 | -1.375 | -42.9017160686 | 3.205 | 3.35 | 1.75 | 804422 | 2.51600905 | CS |
26 | 0.67 | 57.7586206897 | 1.16 | 5.17 | 1.12 | 1527258 | 3.29299144 | CS |
52 | 0.39 | 27.0833333333 | 1.44 | 5.17 | 0.9515 | 1137537 | 2.57933355 | CS |
156 | -13.8 | -88.2917466411 | 15.63 | 18.9583 | 0.5902 | 1189783 | 4.39118668 | CS |
260 | 0.79 | 75.9615384615 | 1.04 | 30.375 | 0.5902 | 1048160 | 7.54704334 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約